Oasmia Pharmaceutical plans to price IPO at $5.75-$7.75 per ADS

Ladenburg Thalmann is bookrunner; Aegis Capital is lead manager

By Susanna Moon

Chicago, Sept. 15 – Oasmia Pharmaceutical AB plans to price its initial public offering of American Depositary Shares at $5.75 and $7.75 per ADS, according to a 424A filing with the Securities and Exchange Commission. The company had registered to sell up to $23 million of shares with a 45-day greenshoe on July 6.

Each ADS represents three of the company’s shares.

The company’s stock (Nasdaq Stockholm: OASM) closed at $2.13 on Aug. 28, based on the foreign exchange rates published by the Federal Reserve Bank of New York that day.

The company has applied to list the ADSs on the Nasdaq under the symbol “OASM.”

Ladenburg Thalmann & Co. Inc. is the bookrunner. Aegis Capital Corp. is the lead manager.

Proceeds will be used to fund new clinical trials, to fund production development, to fund capital expenditures and for other general corporate purposes.

The pharmaceutical company is based in Uppsala, Sweden.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.